Drug Trial Radar · NCT04884256
Safety and Efficacy Study of CBT-004 in Patients With Vascularized Pinguecula
Last checked: Nov 19, 2026Latest source record: Jun 5, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
88
Actual
Start
Dec 21, 2023
Primary completion
Apr 17, 2025
Study completion May 30, 2025
Sponsor
- Lead sponsor
- Cloudbreak Therapeutics, LLCIndustry
- Sponsor type
- Industry
- First posted
- May 12, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
STUDY DESIGN: Structure: Multicenter, randomized, double-masked, vehicle-controlled, parallel-group study. Duration of Treatment: 4 weeks of study treatment with 4 weeks follow-up observations. Control: Vehicle for CBT-004 (hereafter referred to as Vehicle). Masking: Subjects, Investigators, Study Monitors and the Independent Image Reading Center are all masked to the study medications. Dosage/Dose regimen: One drop of the assigned study medication will be administered in the study eye TID for 4 weeks. The study eye is defined as the qualified eye (i.e., the eye meeting the inclusion criterion for vascularized pinguecula). If both eyes are qualified, then the eye with the more severe vascularity grade at Visit 1 will be the study eye.
Conditions
- Pinguecula
Interventions
CBT-004Drug
Dose response study
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from Baseline in conjunctival hyperemia grade at Day 28 (Week 4).Time frame: 1 month
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Global Research Management
Glendale, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.